Onconetix, Inc. Files 8-K: Standard Disclosure

Ticker: ONCO · Form: 8-K · Filed: 2025-03-24T00:00:00.000Z

Sentiment: neutral

Topics: disclosure, filing, sec

TL;DR

Onconetix (ONCO) filed a standard 8-K, no major news.

AI Summary

Onconetix, Inc. filed an 8-K on March 24, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Blue Water Biotech, Inc. and Blue Water Vaccines Inc., is incorporated in Delaware and headquartered in Cincinnati, Ohio. This filing does not contain specific financial figures or material events beyond the standard reporting requirements.

Why It Matters

This 8-K filing serves as a routine update for investors, confirming the company's ongoing compliance and reporting requirements with the SEC.

Risk Assessment

Risk Level: low — The filing is a routine 8-K with no new material information, indicating no immediate change in risk.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Onconetix, Inc.?

The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and to include Financial Statements and Exhibits as of March 24, 2025.

What were the previous names of Onconetix, Inc.?

Onconetix, Inc. was formerly known as Blue Water Biotech, Inc. (name change effective April 24, 2023) and Blue Water Vaccines Inc. (name change effective July 10, 2019).

Where is Onconetix, Inc. incorporated and what is its principal executive office address?

Onconetix, Inc. is incorporated in Delaware and its principal executive offices are located at 201 E. Fifth Street, Suite 1900, Cincinnati, Ohio 45202.

What is the SIC code for Onconetix, Inc.?

The Standard Industrial Classification (SIC) code for Onconetix, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Does this 8-K filing disclose any specific new financial results or material events?

This 8-K filing primarily serves as a current report for Regulation FD Disclosure and Financial Statements and Exhibits, and does not appear to disclose specific new financial results or material events beyond these standard reporting categories.

From the Filing

0001013762-25-001260.txt : 20250324 0001013762-25-001260.hdr.sgml : 20250324 20250324090008 ACCESSION NUMBER: 0001013762-25-001260 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20250324 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250324 DATE AS OF CHANGE: 20250324 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Onconetix, Inc. CENTRAL INDEX KEY: 0001782107 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41294 FILM NUMBER: 25762437 BUSINESS ADDRESS: STREET 1: 201 E. FIFTH STREET STREET 2: SUITE 1900 CITY: CINCINNATI STATE: OH ZIP: 45202 BUSINESS PHONE: 513-620-4101 MAIL ADDRESS: STREET 1: 201 E. FIFTH STREET STREET 2: SUITE 1900 CITY: CINCINNATI STATE: OH ZIP: 45202 FORMER COMPANY: FORMER CONFORMED NAME: Blue Water Biotech, Inc. DATE OF NAME CHANGE: 20230424 FORMER COMPANY: FORMER CONFORMED NAME: Blue Water Vaccines Inc. DATE OF NAME CHANGE: 20190710 8-K 1 ea0235277-8k_oncon.htm CURRENT REPORT false 0001782107 0001782107 2025-03-24 2025-03-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): March 24, 2025   Onconetix, Inc. (Exact name of registrant as specified in its charter)   Delaware   001-41294   83-2262816 (State or other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.)   201 E. Fifth Street , Suite 1900 Cincinnati , Ohio   45202 (Address of Principal Executive Offices)   (Zip Code)   Registrant’s telephone number, including area code: (513) 620-4101     (Former name or former address, if changed since last report.)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of Each Class   Trading Symbol(s)   Name of Each Exchange on Which Registered Common Stock, par value $0.00001 per share   ONCO   The Nasdaq Stock Market LLC   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company ☒   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐              Item 7.01 Regulation FD Disclosure   On March 24, 2025, the Company issued a press release announcing the new clinical data of Proclarix® that was presented on March 23, 2025 at the 2025 European Association of Urology (EAU), which data further demonstrates the strong clinical performance of Proclarix® in a Danish cohort. As previously announced, an abstract including this clinical data wa

View on Read The Filing